Oslo, Norway, 15 September 2022

Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today
announces that following the decisions to discontinue the PARADIGME study for
its lead asset Betalutin[®], restructure the company and appoint Carnegie
Investment Bank to explore strategic options three members of the Company's
Board have decided to step down. Solveig Hellebust, Jean Pierre Bizzari and
Thomas Ramdahl will step down from the Board with immediate effect.

As previously announced in the press release of 18 August 2022 a strategic
exercise led by Carnegie has been initiated with the aim of optimising
shareholder value, following the slow recruitment and subsequent disappointing
data from the PARADIGME clinical trial.

The decision by these Board members to relinquish their Board positions
following the downsizing of the Company will support the preservation of
financial resources during this strategic process while retaining the necessary
personnel needed to maximise the chances of a successful conclusion.

No assurances can be given as to the outcome or timing of the review process
being conducted by Carnegie, but as stated in the Company's recent Q2 results
presentation the review is expected to run into Q4 2022. Nordic Nanovector does
not intend to make any further public comment regarding the review until it has
been completed or the Company determines that disclosure is required or
appropriate.

For further information, please contact:

IR enquiries

Jan H. Egberts, Chairman of Nordic Nanovector
Tel: +31 614672518
Email: janegberts@aol.com

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in radionuclide therapy of cancer. In
addition to Betalutin[®],for which Nordic Nanovector retains global marketing
rights, the Company's novel pipeline includes Humalutin[®], a radioimmunotherapy
candidate based on a chimeric anti-CD37 antibody and the beta emitter lutetium
-177 for NHL